公开(公告)号：EP1745035A1

公开(公告)日：2007-01-24

申请号：EP05708711.6

申请日：2005-03-04

申请人： PFIZER INC.

发明人： YE, Qiang, Pfizer Global Research and Development ,  ZOOK, Scott, Edward ,  OUELLETTE, Michael, Allen ,  HETTINGER, Donald, Nicholas ,  SRIRANGAM, Jayaram K., Pfizer Global Res. & Dev. ,  KANIA, Robert S., Pfizer Global Research and Dev. ,  SAEED, Nabil L., Pfizer Global Research and Dev. ,  WIGHTLIN, Matthew, David ,  MITCHELL, Mark B., Pfizer Global Research and Dev.

IPC分类号： C07D401/14

CPC分类号： C07D401/14

摘要： The invention provides several polymorphic forms and an amorphous form of 2,5-­Dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6­ylamino]-phenyl}-amide, pharmaceutical compositions containing such polymorphic or amorphous forms, and methods of using such pharmaceutical compositions to treat disease states mediated by protein kinases, such as cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation.

公开(公告)号：EP1651608A1

公开(公告)日：2006-05-03

申请号：EP04744013.6

申请日：2004-07-13

申请人： Pfizer Limited ,  PFIZER INC.

发明人： MATHIAS, John Paul

IPC分类号： C07D213/82 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/455 ,  A61P37/00

CPC分类号： C07D213/82 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

摘要： This invention relates to nicotinamide derivatives of general formuala (I) in which R1, R2, and R3 have the meanings defined herein, and to compositions containing and the uses of such derivatives as PDE4 inhibitors.

公开(公告)号：EP1594830A1

公开(公告)日：2005-11-16

申请号：EP04706758.2

申请日：2004-01-30

申请人： Warner-Lambert Company LLC

发明人： PROCTER, Martin, James,OSI Pharmaceuticals ,  GATTRELL, William, Thomas,OSI Pharmaceuticals

IPC分类号： C07C39/17 ,  A61K7/48

CPC分类号： A61Q19/02 ,  A61K8/347 ,  A61K31/05 ,  C07B2200/13 ,  C07C39/17

摘要： The present invention is directed to 4-cyclopentyl resorcinol monohydrate, its Form I polymorph, formulations containing at least one of these compounds, and their use to lighten skin.

公开(公告)号：EP1577292A1

公开(公告)日：2005-09-21

申请号：EP04290724.6

申请日：2004-03-17

申请人： Pfizer Limited

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07C237/42 ,  C07C275/24 ,  C07C311/46 ,  A61K31/166 ,  A61K31/17 ,  A61K31/18 ,  A61P11/08

CPC分类号： C07C237/42 ,  C07C237/20 ,  C07C275/24 ,  C07C311/46

摘要： The invention relates to compounds of formula (1)
and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

公开(公告)号：EP1577291A1

公开(公告)日：2005-09-21

申请号：EP04290725.3

申请日：2004-03-17

申请人： Pfizer Limited

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07C237/20 ,  C07D217/06 ,  A61K31/165 ,  A61K31/472

CPC分类号： C07C237/20 ,  C07C311/46 ,  C07C323/41 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2603/74 ,  C07D217/06 ,  C07F7/1852 ,  C07F7/1856

摘要： The invention relates to compounds of formula (1)
and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

公开(公告)号：EP1572187A1

公开(公告)日：2005-09-14

申请号：EP03777043.5

申请日：2003-12-03

申请人： Warner-Lambert Company LLC

发明人： TAYLOR, Charles, Price, Jr.,Pfizer Global R. & D. ,  THORPE, Andrew, John,Pfizer Global R. and D. ,  WANG, Fong,Pfizer Global Research and Development ,  WUSTROW, David, JuergenPfizer Global R. and D.

IPC分类号： A61K31/197 ,  A61P1/00 ,  A61P25/18 ,  A61P29/00 ,  A61P43/00 ,  A61P5/00

CPC分类号： A61K31/401 ,  A61K31/16 ,  A61K31/18 ,  A61K31/185 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/20 ,  A61K31/4015 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/662 ,  A61K45/06

摘要： The invention relates to a method of treating fibromyalgia and other disorders in a mammal by administering a compound compound of Formula R1 is straight or branched unsubstituted alkyl of from 1 to 5 carbon atoms, unsubstituted phenyl, or unsubstituted cycloalkyl of from 3 to 6 carbon atoms; R2 is hydrogen or methyl; and R3 is hydrogen, methyl, or carboxyl, or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP1542966A1

公开(公告)日：2005-06-22

申请号：EP03754739.5

申请日：2003-09-17

申请人： Pharmacia Corporation

发明人： CHANDRAKUMAR, Nizal, S. ,  DALTON, Christopher, R. ,  MALECHA, James, W. ,  TOLLEFSON, Michael, B. ,  VANCAMP, Jennifer, Ann ,  COX, Phillip, B.

IPC分类号： C07C323/56 ,  C07C323/60 ,  C07C323/62 ,  C07D213/70 ,  C07D213/81 ,  C07D213/82 ,  C07D295/14 ,  C07D295/18 ,  C07D307/14 ,  C07D307/52 ,  C07D317/58 ,  C07D333/38 ,  A61K31/167 ,  A61P9/04

CPC分类号： C07D213/75 ,  C07C323/56 ,  C07C323/60 ,  C07C323/62 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07D213/81 ,  C07D213/82 ,  C07D295/108 ,  C07D295/192 ,  C07D307/14 ,  C07D317/58 ,  C07D333/38

摘要： The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula (I) and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula (I).

摘要翻译： 本发明涉及选择性LXR调节剂，对应于式I的小分子化合物，并且还涉及使用治疗有效剂量的式I化合物治疗由LXR调节的哺乳动物状况的方法。

公开(公告)号：EP1494989A2

公开(公告)日：2005-01-12

申请号：EP03708403.5

申请日：2003-03-24

申请人： WARNER-LAMBERT COMPANY LLC

发明人： FILZEN, Gary, Frederick,Pfizer Global R.& D. ,  TRIVEDI, Bharat, Kalidas,Pfizer Global R.& D. ,  GEYER, Andrew, George,Pfizer Global R.& D. ,  UNANGST, Paul, Charles,Pfizer Global R.& D. ,  BRATTON, Larry, Don,Pfizer Global R.& D. ,  AUERBACH, Bruce, Jeffrey,Pfizer Global R.& D.

IPC分类号： C07C59/70 ,  C07C317/22 ,  C07C323/19 ,  C07D209/10 ,  C07D213/20 ,  C07D213/32 ,  C07D261/08 ,  C07D311/58 ,  C07D405/12 ,  C07D413/12 ,  A61K31/19 ,  A61P3/06 ,  A61P9/10

CPC分类号： C07C323/20 ,  C07C59/70 ,  C07C59/72 ,  C07C317/22 ,  C07C323/19 ,  C07C2602/08 ,  C07C2603/18 ,  C07D209/10 ,  C07D211/14 ,  C07D213/30 ,  C07D213/32 ,  C07D231/12 ,  C07D233/56 ,  C07D233/68 ,  C07D235/18 ,  C07D249/08 ,  C07D261/08 ,  C07D271/06 ,  C07D271/10 ,  C07D295/088 ,  C07D307/79 ,  C07D311/58 ,  C07D333/54 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12

摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

摘要翻译： 本发明自由圆盘化合物没有改变PPAR活性。 因此，本发明光盘松散药学上可接受的化合物的盐，药学上可接受的组合物，包含它们的盐的化合物，以及使用它们作为用于治疗或预防disipidemia，高胆固醇血症，肥胖症，进食障碍，高血糖症，动脉粥样硬化，高甘油三酯血症，高胰岛素血症的治疗剂的方法和 糖尿病的哺乳动物以及抑制食欲和调节哺乳动物中瘦素水平的方法。 本发明的用于在盘化合物游离缺失从而自由圆盘的方法。

公开(公告)号：EP1476157A1

公开(公告)日：2004-11-17

申请号：EP03700974.3

申请日：2003-02-03

申请人： Pfizer Limited ,  PFIZER INC.

发明人： Magee, Thomas Victor

IPC分类号： A61K31/455 ,  A61P29/00 ,  A61P11/00 ,  C07D213/82

CPC分类号： C07D213/82 ,  A61K31/439 ,  A61K31/4433 ,  A61K31/455 ,  A61K45/06 ,  C07D405/12 ,  C07D451/10 ,  A61K2300/00

摘要： The invention relates to nicotinamide derivatives of formula (1) and to processes for the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are phosphodiesterase-4 inhibitors and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions as well as for wounds healing.

公开(公告)号：EP1078924B1

公开(公告)日：2004-10-20

申请号：EP00305987.0

申请日：2000-07-14

申请人： Pfizer Products Inc.

发明人： Scott, Robert William, Pfizer Inc.

IPC分类号： C07D401/04 ,  C07D407/14 ,  C07D213/73

CPC分类号： C07D213/73 ,  C07D401/04 ,  C07D405/14